title: [The Significance and Limitations of Curative Resection for Peritoneal Metastases of Colorectal Cancer].
abstract: The objectives of the present study were to investigate the treatment outcomes of curative resection in patients with peritoneal metastases from colorectal cancer and to clarify the significance and limitations thereof. The study included 38 patients with colorectal cancer who underwent curative resection of peritoneal metastases between 1996 and 2014. Peritoneal metastases were classified as follows: metachronous(n=9)and synchronous(n=29); P1(n=13)and P2(n=25); and ovarian(n=5). Thirty patients received postoperative chemotherapy, includingoxaliplatin -based regimens(n=14)and other regimens, such as 5-FU/Leucovorin(n=16). The 3-year survival rate amongall patients was 59.9%. There were no differences in survival rates accordingto gender, serum CEA levels, location, differentiation, depth of invasion of tumor, number of organs with distant metastases, severity of peritoneal metastasis, and types of postoperative chemotherapy. However, poor outcomes were observed in patients with more advanced lymph node disease and in patients with metachronous metastases compared to those with synchronous metastases. Although curative resection can contribute to long-term survival in colorectal cancer patients with peritoneal metastases, the therapeutic effect may be limited in patients with lymph node metastases and those with metachronous metastases.
authors.affiliation: Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
authors.forename: Hajime
authors.initials: H
authors.lastname: Yokomizo
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Yuki
authors.initials: Y
authors.lastname: Yano
authors.forename: Sachiyo
authors.initials: S
authors.lastname: Okayama
authors.forename: Akiko
authors.initials: A
authors.lastname: Sakuma
authors.forename: Masaya
authors.initials: M
authors.lastname: Satake
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Yamada
authors.forename: Atsuo
authors.initials: A
authors.lastname: Matsumoto
authors.forename: Takebumi
authors.initials: T
authors.lastname: Usui
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Shunichi
authors.initials: S
authors.lastname: Shiozawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimakawa
authors.forename: Takao
authors.initials: T
authors.lastname: Katsube
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kato
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Naritaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents